(Q54226776)

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2907239-6

7 January 2021

Persistence of specific antibodies after hepatitis B vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2907239-6

7 January 2021

Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2907239-6

7 January 2021

Four-year experience with a recombinant hepatitis B vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2907239-6

7 January 2021

Recombinant yeast hepatitis B vaccine compared with plasma-derived vaccine: immunogenicity and effect of a booster dose

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2907239-6

7 January 2021

Immune response to hepatitis B revaccination

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2907239-6

7 January 2021

Is booster injection with hepatitis B vaccine necessary in healthy responders? A study of the immune response

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2907239-6

7 January 2021

Hepatitis B virus. The major etiology of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2907239-6

7 January 2021

Viral hepatitis in children

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2907239-6

7 January 2021

Long-term efficacy of recombinant hepatitis B vaccine and risk of natural infection in infants born to mothers with hepatitis B e antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2907239-6

7 January 2021

Immunogenicity of two recombinant hepatitis B vaccines in older individuals

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2907239-6

7 January 2021

Kinetics of antibody response to hepatitis B virus determinants and to recombinant vaccines in Italy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2907239-6

7 January 2021

Correlation between in vivo humoral and in vitro cellular immune responses following immunization with hepatitis B surface antigen (HBsAg) vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2907239-6

7 January 2021

Protection provided by hepatitis B vaccine in a Yupik Eskimo population--results of a 10-year study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2907239-6

7 January 2021

Response to an extra dose of hepatitis B vaccine and specific antibody persistence in non-responders to primary immunization

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2907239-6

7 January 2021

Persistence of immunologic memory for twelve years in children given hepatitis B vaccine in infancy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2907239-6

7 January 2021

Long-term efficacy of plasma-derived hepatitis B vaccine: a 15-year follow-up study among Chinese children

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2907239-6

7 January 2021

Hepatitis B virus infection in an institution for the mentally retarded

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2907239-6

7 January 2021

A longitudinal study of hepatitis infection in an institution for the mentally retarded.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2907239-6

7 January 2021

Modelling long-term persistence of hepatitis B antibodies after vaccination.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2907239-6

7 January 2021

Hepatitis B vaccination in mentally retarded: Effectiveness after 11 years1To whom it may concern I declare that the parents (guardian) of all subjects have given informed consent and that the study was approved by the ethical committee of the Univer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2907239-6

7 January 2021